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The progressive deterioration associated with
Alzheimer’s disease (AD) results in high economic
cost to the patients, caregivers, and the society as a
whole. Cost-of-AD studies conducted over the last
decade have produced discrepant results, mainly as
a consequence of the different methodologies
employed. The present review is an attempt to pre-
sent the methodology of the cost studies in AD and
provide the reader with the tools necessary for a
critical assessment of the results. 
ecause the prevalence of Alzheimer’s disease
(AD) is age-dependent and the number of the oldest
old is rising, the cost of this disease will increase con-
siderably in the forthcoming decades, without obvious
sources to fund it. This is true in the western world
where the ratio of working force/retirees is decreasing,
1
as well as the third world where progress in health care
has raised the life expectancy. Studies of AD cost con-
ducted over the last decade have produced discrepant
results, a fact that has not prevented interested parties
(consumers,providers,and government agencies) to use
the results to advance their respective,at times opposed,
agendas.The present review is an attempt to present the
limitations of the cost studies in AD and provide the
reader with the tools necessary for a critical assessment
of the results.
What is the cost of AD to society? 
The cost of AD to society is the value of all goods and
services that society gives up in order to prevent, diag-
nose,treat,and deal with the disease.The overall cost is
made up of direct and indirect costs.In addition to these
costs,society also absorbs expenses associated with AD
research and education programs.
2 Table I summarizes
the definitions of different costs and provides some
examples of the components of the cost of AD.
Reasons for discrepancies in the results 
of cost-of-illness studies on AD
As often in economic analysis, results depend on study
methodologies, which can differ in many aspects, thus
leading to significant discrepancies. In the USA, for
example, the annual cost of caring for an AD patient
ranges from $27 700 to $47 000 (see Table II).Following
are a number of examples illustrating how the method-
ology employed to calculate the cost affects the final
results.The first type of examples relates mainly to the
reliability and accuracy of the data collected, while the
second type relates directly to the methods by which
the cost itself is calculated.
Some of the published studies on cost of AD follow
cohorts of patients prospectively,while other studies col-
lect data retrospectively. Also, some studies interview
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Bcaregivers,and others use patients’ medical records and
insurance databases. Each method presents advantages
and disadvantages. Retrospective data obtained from
databases are not dependent on the caregiver recol-
lection and interpretation. On the other hand, data-
bases belonging to medical insurance companies and
other medical databases contain information on direct
cost, but no data on indirect cost. Finally, prospective
studies, which supply the most complete set of data,
are very expensive to conduct and are biased by the
fact that they include selected patient populations who
seek help in academic centers where such studies are
conducted.
As presented in Table II, the length of time covered by
the study—which varies from 1 month to 12 months—
also affects the final results. The longer information is
collected, the more stable and generalizable are the
results.For example,a single respite hospitalization of an
158
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Component of cost Definition Example
Direct cost Goods and services for which money  Physicians’ fees, fees for 
is explicitly exchanged hospitalization, 
nursing home, drugs
Indirect cost Resource lost or invested for which  Unpaid care and services 
no money is exchanged provided by family members, years of 
productive life lost because of the illness
Cost of research Research devoted to AD Government funding discovery of 
diagnostic and treatment tools, 
epidemiology and pathogenesis of AD
Cost of education Training staff to care for patients,  Nursing, 
training researchers training of caregivers
Country Cost year Annual cost  Type of study Participating  N Reference
per patient groups
USA 1990 $47 000 Prospective (12 months) Community and institution 187 Rice et al,
3 1993
USA 1991 $33 600- Data from published  
__ __
Ernst & Hay,
4 1994
$35 000* resources and
other researchers
UK 1994 $75 000 Retrospective (3 months) Community and control 128 Souetre et al,
5 1999
USA 1996 $27 700 Retrospective (1 month) Academic medical center,  679 Leon et al,
6 1998
managed care plan, 
assisted living facility, 
and nursing home
Canada 1996 $9451- Retrospective (1 month) Community and institution 750 Hux et al,
7 1998
$36 794†
Israel 1999 $16 330-26 900‡ Prospective (6 months) Community, institution,  121 Beeri et al,
8
and control in preparation
Table I. Components of cost of Alzheimer’disease (AD).
Table II. Cost-of-illness studies. (Numbers are rounded.) * First number,cost of first year; second number, cost of second and later years.
† First number, mild disease severity; second number, severe disease.
‡ First number, community-dwelling patient’s cost; second number, 
institutionalized patient’s cost.159
AD patient for 1 week would increase significantly the
cost of care if the follow-up period is 1 month,but would
not make a significant difference if this cost is spread
over a 12-month follow-up study. Similarly, in any kind
of clinical study, results are more representative when
the sample size is larger, yet cost studies of AD report
samples ranging from 120 to 750 subjects (Table II).
3-8A
corollary problem is that some,
3 but not all
6,7 of the sam-
ples cover a very specific geographic area and specific
populations.Specific populations may have a health ser-
vice utilization profile that differs from the general pop-
ulation, and, not surprisingly, in higher-level socioeco-
nomic geographic areas, the out-of-pocket expenses on
health services are higher than in a poorer area. Also,
some studies employ a control group, while others do
not. Having or not a control group of nondemented
elderly helps account for the cost associated with other
comorbid, age-related diseases, hence highlighting the
costs specifically related to AD.
Even when studies survey similar populations for similar
period of times, there are still large discrepancies
between results of the studies related to the components
that are included in the calculations and summation of
the total cost of AD.For example,one study included as
direct cost fees for the general practitioner and as indi-
rect cost lost years of productive life.On the other hand,
in the same study,the indirect economic burden imposed
on family members was not included.
9 In contrast, very
detailed direct and indirect care costs were estimated in
a study carried out in the US,
3 but this analysis did not
include the cost of the productive years lost because of
the illness.
Not only the components included in calculating the
total cost of illness differ between studies, but also the
definition of each component.For example,it is not easy
to decide whether a particular activity constitutes spend-
ing leisure time with a sick spouse or should be consid-
ered an effort related to the patient’s care and there-
fore part of the indirect cost.Is watching a TV program
with a patient, who, if left alone, will leave the house,
get lost,and maybe harm him- or herself in the process,
leisure or supervision?
Finally, even if the methodologies are impeccable, the
components of cost utilized to come up with a total cost
identical, and the definition-of-cost components identi-
cal between studies, comparison between studies con-
ducted in different countries can only be interpreted if
considered relatively to the average wage or acquisition
power of the citizens of the respective country.
Other types of cost analysis
Although cost-of-illness studies are important by them-
selves and serve as basis for social and health care policy
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Type of analysis Definition Example
Cost-effectiveness Cost of care is related to a nonmonetary  Comparison of caregiver burden in AD
outcome measure patients who participate and who 
do not participate in day care
Cost-benefit Both costs and benefits are expressed  The cost of a medication to treat 
in monetary terms AD compared with the monetary 
benefit resulting from delayed 
institutionalization
Cost-minimization Outcome is assumed or proven to be equal,  Comparison of prices of two medications 
and the purpose is to identify  for AD that have the same therapeutic effect
the cheapest alternative
Cost-utility Costs are related to well-being  A medication to treat AD that improves
or QALY  quality of life by 0.2 for each of 5 patients
will result in the equivalent of 1 QALY if 
the benefit is maintained over 
a 1-year period
Table III. Type of cost analysis. AD, Alzheimer’s disease; QALY, quality-adjusted life years.debate, they do not enable alternatives to be assessed.
Studies that assess alternatives are called cost-effective-
ness analyses, cost-benefit analyses, cost-minimization
analyses,and cost-utility analyses,and are summarized in
Table III.The goal of these analyses is to find the alter-
native that provides the best care for the lowest cost,or
even better,describes the optimal balance between ben-
efits and costs.
10 For example,results of a study evaluat-
ing cost effectiveness of day care for patients with
dementia indicated that it was less expensive to pay for
day care than to incur the indirect,informal and formal,
cost associated with keeping the patient at home.
11
Pharmacoeconomic studies are health economic stud-
ies used increasingly by insurance companies, govern-
ments, and other providers of health services to decide
whether to adopt a new drug. Because the efficacy of
anti-AD drugs is not very great, the issue of cost effec-
tiveness was raised as soon as these drugs were
approved for marketing. For example, in a study of
donepezil’s effect on health care cost and utilization,
potential savings derived from decrease in medical cost
were found to be neutralized by increase in the direct
cost due to the high cost of medication.
12
Nevertheless, there is a trend indicating that these treat-
ments have the potential to offer cost savings,
12-14 but these
trends are mostly expressed as economic models rather
than real-life studies. For example, in some studies,
13,15
tacrine reduced the cost of caring for an AD patient by
reducing cost of both institutionalization and home care.
Finally, in a recent Canadian study, it was found that
rivastigmine delayed the transition to more severe stages
of AD.As severity of illness is related to higher costs,the
consequence of this delay is cost savings.
16The main lim-
itation of pharmacoeconomic studies is that they are very
rarely designed a priori to address pharmacoeconomic
questions.Most often,they are pivotal phase 3 drug trials,
to which secondary measurements addressing pharma-
coeconomics are added. Hence, they suffer from all the
limitations of controlled trials (selected patient popula-
tions, restricted outcome measurements and laboratory
instead of real life clinical care).
Whose costs are we measuring? 
In the final analysis, whether a treatment, intervention,
or service is cost-effective depends very much on who is
paying for it.
17 Too often, “novel, innovative” interven-
tions and services result in cost shifting rather than sav-
ing resources or providing better care. For example,
depending on the organization of health care and the
insurance status of the patient, the transfer of a patient
from home to institutionalization may decrease the fam-
ily out-of-pocket expenses and increase the insurer
expenses, who now has to cover the cost of institution-
alization. Similarly, a drug that delays institutionaliza-
tion might increase the expenses of the local authori-
ties, which are often covering the cost of day-care
centers, and decrease the cost of the private or govern-
mental insurance agency that covers the cost of a nursing
home.Finally,indirect cost related to the care provided
for free by a healthy spouse or child has monetary
meaning only if the caregiver can obtain gainful employ-
ment instead of being a caregiver. This is particularly
relevant in AD where most of the caregivers are spouses
who are often,but not always,retired.In this case,qual-
ity of life rather than cost is the relevant variable, but
pricing the quality of life of a demented individual or
even of an elderly caregiver is a daunting task.
In summary, because economic considerations are
expected to play an increasing role in the medical deci-
sion-making process including new interventions for
AD, health-care workers should familiarize themselves
with cost-analysis techniques and become critical con-
sumers of the literature describing these analyses.This
will prevent interested parties from using meaningless
numbers to advance partisan agendas. ❏
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Costo de la Enfermedad de Alzheimer
El deterioro progresivo que se asocia con la Enfermedad de
Alzheimer (EA) se traduce en un alto costo económico para
los pacientes, los cuidadores y la sociedad en su conjunto.
Los estudios acerca del costo de la EA realizados en la últi-
ma década han producido resultados discrepantes, princi-
palmente debidos a las diferentes metodologías utilizadas.
Este artículo de revisión intenta presentar la metodología
empleada en los estudios de costo en la EA y entregar al lec-
tor las herramientas necesarias para una evaluación crítica
de los resultados.
Coût de la maladie d’Alzheimer
La détérioration progressive de l’état de santé liée à la mala-
die d’Alzheimer est à l’origine du coût économique impor-
tant pour les patients,le personnel soignant et la société dans
son ensemble.Les études de coût de cette maladie menées au
cours de la dernière décennie ont donné des résultats diver-
gents, dus principalement à l’utilisation de méthodologies
différentes.Cet article s’efforce de présenter la méthodologie
des études de coût de la maladie d’Alzheimer et de fournir
au lecteur tous les outils nécessaires à une évaluation cri-
tique de ces résultats.
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